Immunobiology of head and neck cancer
- PMID: 15785875
- DOI: 10.1007/s10555-005-5050-6
Immunobiology of head and neck cancer
Abstract
The development of head and neck cancer (HNC) is strongly influenced by the host immune system. Recent evidence for the presence of functional defects and for apoptosis of tumor-infiltrating as well as circulating T cells in patients with HNC emphasizes the fact that their antitumor responses are compromised. It appears that H&N tumors not only effectively escape from the host immune system but also actively corrupt the host antitumor response via several distinct mechanisms. Strategies for restoring immune competence of patients with HNC and for preventing tumor escape are necessary for more effective control of tumor progression. New immunotherapeutic approaches include cytokine-based and DC-based vaccines which are aimed at the restoration of tumor-specific responses and at the protection of immune cells from tumor-induced apoptosis.
Similar articles
-
Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies.Head Neck. 2010 Jul;32(7):946-58. doi: 10.1002/hed.21346. Head Neck. 2010. PMID: 20191626 Review.
-
Immunobiology and immunotherapy of head and neck cancer.Curr Oncol Rep. 2001 Jan;3(1):46-55. doi: 10.1007/s11912-001-0042-3. Curr Oncol Rep. 2001. PMID: 11123869 Review.
-
Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?Head Neck. 2008 Feb;30(2):251-61. doi: 10.1002/hed.20739. Head Neck. 2008. PMID: 18172882 Review.
-
Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers.Oral Oncol. 2008 Jul;44(7):672-82. doi: 10.1016/j.oraloncology.2007.08.013. Epub 2007 Nov 8. Oral Oncol. 2008. PMID: 17996489
-
Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?ORL J Otorhinolaryngol Relat Spec. 2004;66(6):332-40. doi: 10.1159/000081891. ORL J Otorhinolaryngol Relat Spec. 2004. PMID: 15668533 Review.
Cited by
-
Eosinophils and oral squamous cell carcinoma: a short review.J Oncol. 2009;2009:310132. doi: 10.1155/2009/310132. Epub 2009 Dec 16. J Oncol. 2009. PMID: 20049171 Free PMC article.
-
Immune suppression in head and neck cancers: a review.Clin Dev Immunol. 2010;2010:701657. doi: 10.1155/2010/701657. Epub 2011 Mar 10. Clin Dev Immunol. 2010. PMID: 21437225 Free PMC article. Review.
-
Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.Med Oncol. 2017 Apr;34(4):60. doi: 10.1007/s12032-017-0918-1. Epub 2017 Mar 17. Med Oncol. 2017. PMID: 28315228 Free PMC article. Review.
-
RNA-binding protein HuR reprograms immune T cells and promotes oral squamous cell carcinoma.Oral Oncol Rep. 2024 Jun;10:100296. doi: 10.1016/j.oor.2024.100296. Epub 2024 Mar 21. Oral Oncol Rep. 2024. PMID: 38681116 Free PMC article.
-
TNF Patterns and Tumor Microenvironment Characterization in Head and Neck Squamous Cell Carcinoma.Front Immunol. 2021 Oct 6;12:754818. doi: 10.3389/fimmu.2021.754818. eCollection 2021. Front Immunol. 2021. PMID: 34691075 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical